Biocytogen Pharmaceuticals (Beijing) Co Ltd Sustainability Reports
The company operates as a global biotechnology enterprise focusing on antibody-based drug discovery, gene-editing services, and preclinical pharmacology evaluations. It provides off-the-shelf humanized animal models and fully human antibody sequences for worldwide biomedical collaborations.
Sector: Manufacturing
Country: China
Exchange: Hong Kong Stock Exchange
LEI: 549300F4L1TRSHBRCU87
FIGI: BBG00KK8MLD0
5 reports from 2022 to 2025
- Biocytogen Pharmaceuticals (Beijing) Co Ltd 2025 Environmental, Social and Governance Report
- Biocytogen Pharmaceuticals (Beijing) Co Ltd 2025 Annual Report
- Biocytogen Pharmaceuticals (Beijing) Co Ltd 2024 Annual Report
- Biocytogen Pharmaceuticals (Beijing) Co Ltd 2023 Annual Report
- Biocytogen Pharmaceuticals (Beijing) Co Ltd 2022 Annual Report